Use: Labeled indications
- HUMULIN R U-500 is a concentrated human insulin indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE HUMULIN R U-500 is a concentrated human insulin indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day. HUMULIN ® R U-500 is a concentrated human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day.
(1) Limitation of Use: The safety and efficacy of HUMULIN R U-500 used in combination with other insulins has not been determined. The safety and efficacy of HUMULIN R U-500 delivered by continuous subcutaneous infusion has not been determined. (1.1) 1.1 Limitation of Use The safety and efficacy of HUMULIN R U-500 used in combination with other insulins has not been determined.
The safety and efficacy of HUMULIN R U-500 delivered by continuous subcutaneous infusion has not been determined.
Contraindications
4 CONTRAINDICATIONS HUMULIN R U-500 is contraindicated: During episodes of hypoglycemia [see Warnings and Precautions (5.3)] In patients who are hypersensitive to HUMULIN R U-500 or any of its excipients [see Warnings and Precautions (5.4)] Do not use during episodes of hypoglycemia. (4) Do not use in patients with hypersensitivity to HUMULIN R U-500 or any of its excipients. (4)
US FDA labelDosing: Adult
- Adhere to administration instructions to reduce the risk of dosing errors. (2.1, 2.3)
- HUMULIN R U-500 is available as a single-patient-use KwikPen. (2.1)
- Individualize dose of HUMULIN R U-500 based on metabolic needs, blood glucose monitoring results and glycemic control goal. (2.2)
- Administer HUMULIN R U-500 subcutaneously two or three times daily 30 minutes before a meal into the thigh, upper arm, abdomen, or buttocks. Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. (2.1, 2.2)
- Do NOT mix HUMULIN R U-500 with other insulins. (2.1)
- Do NOT administer HUMULIN R U-500 intravenously (2.1)
- Do NOT perform dose conversion when using the HUMULIN R U-500 KwikPen. The dose window of the HUMULIN R U-500 KwikPen shows the number of units of HUMULIN R U-500 to be injected. (2.3)
- Do NOT transfer HUMULIN R U-500 from the HUMULIN R U-500 KwikPen into any syringe. (2.3)
2.1 Important Administration Instructions Prescribe
2.1 Important Administration Instructions Prescribe HUMULIN R U-500 ONLY to patients who require more than 200 units of insulin per day. HUMULIN R U-500 is available as a single-patient-use KwikPen. Instruct patients to always check the insulin label before administration to confirm the correct insulin product is being used.
Inspect HUMULIN R U-500 visually for particulate matter and discoloration. Only use HUMULIN R U-500 if the solution appears clear and colorless. Instruct patients to inject HUMULIN R U-500 subcutaneously into the thigh, upper arm, abdomen, or buttocks. Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2) and Adverse Reactions (6)]. During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)]. Use HUMULIN R U-500 KwikPen with caution in patients with visual impairment that may rely on audible clicks to dial their dose.
DO NOT administer HUMULIN R U-500 intravenously. DO NOT dilute or mix HUMULIN R U-500 with any other insulin products or solutions.
2.2 Dosing Instructions
2.2 Dosing Instructions Instruct patients to inject HUMULIN R U-500 subcutaneously usually two or three times daily approximately 30 minutes before meals. Individualize and titrate the dosage of HUMULIN R U-500 based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal. Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function, changes in medications or during acute illness to minimize the risk of hypoglycemia or hyperglycemia [see Warnings and Precautions (5.2)].
2.3 Delivery
2.3 Delivery of HUMULIN R U-500 Using the HUMULIN R U-500 Disposable Prefilled KwikPen Device The HUMULIN R U-500 KwikPen dials in 5 unit increments and delivers a maximum dose of 300 units per injection. DO NOT perform dose conversion when using the HUMULIN R U-500 KwikPen. The dose window of the HUMULIN R U-500 KwikPen shows the number of units of HUMULIN R U-500 to be injected and NO dose conversion is required.
DO NOT transfer HUMULIN R U-500 from the HUMULIN R U-500 KwikPen into any syringe for administration as overdose and severe hypoglycemia can occur [see Warnings and Precautions (5.3)].
Dosing: Altered kidney function
8.6 Renal Impairment Frequent glucose monitoring and insulin dose reduction may be required in patients with renal impairment.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment Frequent glucose monitoring and insulin dose reduction may be required in patients with hepatic impairment.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of HUMULIN R U-500 in pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day to improve glycemic control have been established. Use of HUMULIN R U-500 for this indication is supported by evidence from studies with other insulin human in pediatric patients with type 1 diabetes mellitus and from studies in adults with diabetes mellitus. Standard precautions as applied to use of HUMULIN R U-500 in adults are appropriate for use in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use The effect of age on the pharmacokinetics and pharmacodynamics of HUMULIN R U-500 has not been studied. Caution should be exercised when HUMULIN R U-500 is administered to geriatric patients. In elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemia.
Administration
2.1 Important Administration Instructions Prescribe HUMULIN R U-500 ONLY to patients who require more than 200 units of insulin per day. HUMULIN R U-500 is available as a single-patient-use KwikPen. Instruct patients to always check the insulin label before administration to confirm the correct insulin product is being used. Inspect HUMULIN R U-500 visually for particulate matter and discoloration. Only use HUMULIN R U-500 if the solution appears clear and colorless. Instruct patients to inject HUMULIN R U-500 subcutaneously into the thigh, upper arm, abdomen, or buttocks. Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] . Use HUMULIN R U-500 KwikPen with caution in patients with visual impairment that may rely on audible clicks to dial their dose. DO NOT administer HUMULIN R U-500 intravenously. DO NOT dilute or mix HUMULIN R U-500 with any other insulin products or solutions.
US FDA labelDosage forms
Philippines
- Suspension for injection: 100 IU/mL
- Solution for injection: 100 IU/mL
- Suspension for injection suspension for injection: 100 IU/mL
Registered products in the Philippines
36 products registered with the Food and Drug Administration (FDA) Philippines list Insulin human as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Human Insulin (rDNA) (1 product). Products registered under these spellings are included in the table and marked.
All registered products36
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
100 IU/mL Solution for Injection (IM/IV/SC)Ph. Eur. Type I Glass Vial with latex free laminated rubber disc cap x 10 mL (Box of 1's) | RxVAT-exempt | Novo Nordisk A/SDenmark | NOVO NORDISK PHARMACEUTICALS (PHILIPPINES), INC. | BR-1008 | May 6, 2029 | ||
ActrapidInsulin Human (Regular) | 100 IU/mL Solution for Injection (SC)Type I glass vial closed with a disc (bromobutyl/polyisoprene rubber) and a protective tamper-proof plastic cap containing 10 mL of suspension (Box of 1's) | RxVAT-exempt | Novo Nordisk Production SASFrance | Novo Nordisk Pharmaceuticals (Philippines), Inc. | BR-1219 | Jun 2, 2027 | |
Biosulidd 30:70Insulin Human (rDNA) | 100 IU/mL (30% Soluble Insulin Human / 70% Isophane Insulin Human) Suspension for Injection (IM/SC)USP Type I vial x 10 mL (Box of 1's) | RxVAT-exempt | M.J. Biopharm Pvt., Ltd.India | Aristo Pharma Philippines, Inc.Importer: PNF Pharmaceutical, Inc. | BRP-074 | Feb 23, 2027 | |
Duosulin 30:70Insulin Human (DNA) | 100 IU/mL (30% Soluble Insulin Human / 70% Isophane Insulin Human) Suspension for Injection (IM/SC)USP Type I vial x 10 mL (Box of 1's) | RxVAT-exempt | M.J. Biopharm Pvt., Ltd.India | Duopharma Trade Phils., Inc.Importer: PNF Pharmaceutical, Inc. | BRP-074-02 | Feb 23, 2027 | |
Duosulin NInsulin Human (rDNA) | 100 IU/mL (100% Isophane Insulin Human) Suspension for Injection (IM/SC)USP Type I Clear, colorless glass vial with green flip-off seal x 10 mL (Box of 1's) | RxVAT-exempt | M.J. Biopharm Pvt., Ltd.India | Duopharma Trade Phils., Inc.Importer: PNF Pharmaceutical, Inc. | BRP-065-02 | Aug 28, 2031 | |
Duosulin RInsulin Human (rDNA) | 100 IU/mL Solution for Injection (IM/SC)USP Type I Glass Vial with Yellow flip off seal x 10 mL (Box of 1s) | RxVAT-exempt | MJ Biopharm Pvt., Ltd.India | Duopharma Trade Phils., Inc.Importer: PNF Pharmaceutical, Inc. | BRP-066-02 | Jun 5, 2031 | |
Glysolin 30/70Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)USP Type I clear and colourless glass cartridge x 3 mL (Box of 1's) | RxVAT-exempt | Wockhardt LimitedIndia | The Cathay YSS Distributors Co., IncImporter: Ambica International Corporation | BRP-054-01 | Feb 10, 2029 | |
Glysolin NInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)USP Type I clear and colourless glass cartridge x 3 mL (Box of 1's) | RxVAT-exempt | Wockhardt LimitedIndia | The Cathay YSS Distributors Co., IncImporter: Ambica International Corporation | BRP-038-01 | Mar 29, 2029 | |
Humulin 70/30Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC) (70% Isophane Insulin Human/ 30% Soluble Insulin Human)10 mL Type I clear and colorless glass vial Box of 1's | RxVAT-exempt | Eli Lilly and CompanyUSA | ZUELLIG PHARMA CORPORATION | BR-977 | Jul 21, 2028 | |
Humulin 70/30 KwikpenInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC) 70% Isophane + 30% Soluble Human Insulin (rDNA Origin)Pre-filled pen x 3 mL (Box of 5's) | RxVAT-exempt | Lilly France (Fegersheim)France | ZUELLIG PHARMA CORPORATION | BR-950 | May 27, 2029 | |
Humulin NInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)10mL Type 1 flint glass vial with rubber stopper, sealed with aluminum crimp and yellow green flip-off cap (Box of 1's) | RxVAT-exempt | Eli Lily and CompanyUSA | Zuellig Pharma Corporation | BR-962 | Apr 20, 2031 | |
Humulin N KwikpenInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)Pre-filled pen x 3 mL (Box of 5's) | RxVAT-exempt | Lilly France FegersheimFrance | ZUELLIG PHARMA CORPORATION | BR-948 | May 27, 2029 | |
Humulin RInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC/IV)Clear colourless glass vial with yellow flip-off seal x 10 mL (Box of 1's) | RxVAT-exempt | Eli Lily and CompanyUSA | Zuellig Pharma Corporation | BR-980 | May 22, 2031 | |
Insugen-30/70 (Biphasic)Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)USP Type I Glass Vial x 10 mL (Box of 1's) | RxVAT-exempt | Biocon Biologics LimitedIndia | Biocon Biologics Philippines Inc. | BR-997 | Nov 5, 2031 | |
Insugen-R (Regular)Insulin Human (rDNA) | 100 IU/mL Solution for Injection (SC)USP Type I Glass Vial x 10 mL (Box of 1's) | RxVAT-exempt | Biocon Biologics LimitedIndia | Biocon Biologics Philippines Inc. | BR-995 | Nov 5, 2031 | |
Insuget 70/30Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC)Glass vial with white flip-off cap x 10mL (Box of 1’s) | RxVAT-exempt | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | BR-1088 | Jan 6, 2030 | |
Insuget-NInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC)Glass vial with green flip-off cap x 10mL (Box of 1’s) | RxVAT-exempt | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | BR-1102 | Jan 6, 2030 | |
Insuget-RInsulin Human (rDNA) | 100 IU/mL Solution for Injection (IM/IV/SC)Glass vial with yellow flip-off cap x 10mL (Box of 1’s) | RxVAT-exempt | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | BR-1103 | Jan 6, 2030 | |
InsulatardInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)Type I glass vial x 10 mL (Box of 1's) | RxVAT-exempt | Novo Nordisk A/SDenmark | NOVO NORDISK PHARMACEUTICALS (PHILIPPINES), INC. | BR-1010 | Aug 20, 2028 | |
Insulet 30/70Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC)USP Type II clear glass vial with red flip-off seal x 4 mL and 10 mL (Box of 1's) | RxVAT-exempt | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | BRP-017 | Oct 24, 2028 | |
Insulet 50/50Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC)USP Type II clear glass vial with blue flip-off seal x 4 mL and 10 mL (Box of 1's) | RxVAT-exempt | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | BRP-018 | Oct 24, 2028 | |
Insulet NInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC)USP Type II clear glass vial with green flip-off seal x 4 mL and 10 mL (Box of 1's) | RxVAT-exempt | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | BRP-020 | Oct 24, 2028 | |
Insuljack 30:70Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC) (30% Soluble Insulin Human/ 70% Isophane Insulin Human)USP Type I vial x 10 mL (Box of 1's) | RxVAT-exempt | M.J. Biopharm Pvt., Ltd.India | Jackpharma Inc.Importer: PNF Pharmaceutical, Inc. | BRP-074-03 | Feb 23, 2027 | |
Insunova 30:70Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC) (30% Soluble Insulin Human/70% Isophane Insulin Human)USP Type I vial x 10mL (Box of 1's) | RxVAT-exempt | M.J. Biopharm Pvt., Ltd.India | Mega Lifesciences Limited Inc.Importer: PNF Pharmaceutical, Inc. | BRP-074-04 | Feb 23, 2027 | |
Lupinsulin 30:70Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (IM/SC) (30% Soluble Insulin Human / 70% Isophane Insulin Human) Suspension for Injection (IM/SC)USP Type I vial x 10 mL (Box of l's) | RxVAT-exempt | M.J. Biopharm Pvt., Ltd.India | Multicare Pharmaceuticals Phils., Inc.Importer: PNF Pharmaceutical, Inc. : | BRP-074-01 | Feb 23, 2027 | |
Lupinsulin RInsulin Human (rDNA) | 100 IU/mL Solution for Injection (IM/SC)USP Type l Glass Vial with Yellow Flip-Off Seal x 10mL (Box of 1's) | RxVAT-exempt | MJ Biopharm Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc.Importer: PNF Pharmaceutical, Inc. | BRP-066-01 | Jun 5, 2031 | |
NoneInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)USP Type I clear and colourless glass cartridge x 3 mL (Box of 1's) | RxVAT-exempt | Wockhardt LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | BRP-038-02 | Mar 29, 2029 | |
NoneInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)USP Type I clear and colourless glass cartridge x 3 mL (Box of 1's) | RxVAT-exempt | Wockhardt LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | BRP-054-02 | Feb 10, 2029 | |
Scilin M30Insulin Human (rDNA) | 30 % Soluble Insulin + 70 % Isophane Insulin 100 IU/mL Suspension for Injection (SC)3 mL Clear and Colorless Glass Cartridge (Box of 5's) | RxVAT-exempt | Bioton S.A.Poland | Metro Drug, Inc.Trader: Scigen Ltd. | BRP-125 | Oct 4, 2030 | |
Scilin M30Insulin Human (rDNA) | 30% Soluble Insulin + 70% Isophane Insulin 100 IU/mL Suspension for Injection (SC)Clear and colorless glass vial X 10 mL with combiseal (Box of 1's) | RxVAT-exempt | Bioton S.A.Poland | Metro Drug, Inc.Trader: SciGen Ltd. | BRP-124 | Apr 5, 2029 | |
Scilin NInsulin Human (rDNA) | Isophane 100 IU/ mL Suspension for Injection (SC)Clear and colorless glass vial x 10 mL (Box of 1's) | RxVAT-exempt | Bioton S.A.Poland | Metro Drug, Inc.Trader: SciGen Ltd. | BRP-127 | Oct 28, 2030 | |
Scilin NInsulin Human (rDNA) | Isophane 100 IU/mL Suspension for Injection (SC)3 mL Clear and Colorless Glass Cartridge (Box of 5's) | RxVAT-exempt | Bioton S.A.Poland | Metro Drug, Inc.Trader: SciGen Ltd. | BRP-126 | Oct 4, 2030 | |
Scilin RInsulin Human (rDNA) | 100 IU/mL Solution for Injection (IV/SC)3mL glass cartridge (Box of 5's) | RxVAT-exempt | Bioton SAPoland | Metro Drug, Inc.Trader: Scigen Limited | BRP-128 | Jan 28, 2030 | |
Scilin RInsulin Human (rDNA) | 100IU/mL Solution for Injection (IV/SC)Clear and colorless glass vial with red flip-off cap x 10mL (Box of 1's) | RxVAT-exempt | Bioton S.A.Poland | Metro Drug, Inc.Trader: Scigen Limited | BRP-129 | Jan 28, 2030 | |
Wosulin-30/70Insulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)USP Type I clear and colourless glass cartridge x 3 mL (Box of 1's) | RxVAT-exempt | Wockhardt LimitedIndia | Ambica International Corporation | BRP-054 | Feb 10, 2029 | |
Wosulin-NInsulin Human (rDNA) | 100 IU/mL Suspension for Injection (SC)USP Type I clear and colourless glass cartridge x 3 mL (Box of 1's) | RxVAT-exempt | Wockhardt LimitedIndia | Ambica International Corporation | BRP-038 | Mar 29, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 500 units/mL (U-500) clear, colorless solution available as: 3 mL single-patient-use HUMULIN R U-500 KwikPen prefilled pen (containing 1,500 units of insulin) Injection: 500 units/mL (U-500) available as: (3) 3 mL single-patient-use HUMULIN ® R U-500 KwikPen ® prefilled pen (containing 1,500 units of insulin)
Warnings/Precautions
- Never share a HUMULIN R U-500 KwikPen between patients, even if the needle is changed. (5.1)
- Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. (5.2)
- Hypoglycemia: May be life-threatening. Increase monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness. (5.3)
- Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue HUMULIN R U-500, monitor, and treat if indicated. (5.4)
- Hypokalemia: May be life-threatening. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated. (5.5)
- Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs. (5.6)
5.1 Never Share
5.1 Never Share a HUMULIN R U-500 KwikPen Between Patients HUMULIN R U-500 KwikPens should never be shared between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
5.2 Hyperglycemia or Hypoglycemia with Changes
5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions (5.3)] or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia [see Adverse Reactions (6)].
Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia.
For patients with type 2 diabetes, adjustments in concomitant oral anti-diabetic treatment may be needed.
5.3 Hypoglycemia
5.3 Hypoglycemia Hypoglycemia is the most common adverse reaction associated with insulins, including HUMULIN R U-500. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Severe hypoglycemia may develop as long as 18 to 24 hours after an injection of HUMULIN R U-500. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving, or operating other machinery).
Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia.
Risk Factors for Hypoglycemia The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation. As with all insulin preparations, the glucose lowering effect time course of HUMULIN R U-500 may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature.
Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to concomitant drugs [see Drug Interactions (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].
Risk Mitigation Strategies for Hypoglycemia Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
To minimize the risk of hypoglycemia do not administer HUMULIN R U-500 intravenously or in an insulin pump or dilute or mix HUMULIN R U-500 with any other insulin products or solutions [see Dosage and Administration (2.1)].
5.4 Hypersensitivity Reactions
5.4 Hypersensitivity Reactions Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including HUMULIN R U-500. If hypersensitivity reactions occur, discontinue HUMULIN R U-500; treat per standard of care and monitor until symptoms and signs resolve [see Adverse Reactions (6)].
5.5 Hypokalemia
5.5 Hypokalemia All insulins, including HUMULIN R U-500, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).
5.6 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists…
5.6 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including HUMULIN R U-500, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure.
If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Table 1: Clinically Significant Drug Interactions with HUMULIN R U-500 Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN R U-500 is co-administered with these drugs.
Drugs That May Decrease the Blood Glucose Lowering Effect of HUMULIN R U 500 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN R U-500 is co-administered with these drugs.
Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of HUMULIN R U 500 Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN R U-500 is co-administered with these drugs.
Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine Intervention: Increased frequency of glucose monitoring may be required when HUMULIN R U-500 is co-administered with these drugs. Drugs that Affect Glucose Metabolism: Adjustment of insulin dosage may be needed.
(7) Antiadrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Signs and symptoms of hypoglycemia may be reduced or absent. (5.2, 7)
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere: Hypoglycemia [see Warnings and Precautions (5.3)]. Hypersensitivity Reactions [see Warnings and Precautions (5.4)]. Hypokalemia [see Warnings and Precautions (5.5)]. The following additional adverse reactions have been identified during post-approval use of HUMULIN R U-500.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Adverse reactions associated with HUMULIN R U-500 include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.
(6) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Hypoglycemia Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including HUMULIN R U-500. Allergic Reactions Severe, life-threatening, generalized allergy, including anaphylaxis, generalized skin reactions, rash, angioedema, bronchospasm, hypotension, and shock may occur with insulins, including HUMULIN R U-500 and may be life threatening.
Lipodystrophy Long-term use of insulin, including HUMULIN R U-500, can cause lipodystrophy at the site of repeated insulin injections. Lipodystrophy includes lipohypertrophy (thickening of adipose tissue) and lipoatrophy (thinning of adipose tissue) and may affect insulin absorption. Rotate insulin injections sites within the same region to reduce the risk of lipodystrophy [see Dosage and Administration (2.1)].
Localized Cutaneous Amyloidosis Localized cutaneous amyloidosis at the injection site has occurred. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site. Injection Site Reactions Patients taking HUMULIN R U-500 may experience injection site reactions, including injection site hematoma, pain, hemorrhage, erythema, nodules, swelling, discoloration, pruritus, warmth, and injection site mass.
Weight Gain Weight gain can occur with insulins, including HUMULIN R U-500, and has been attributed to the anabolic effects of insulin. Peripheral Edema Insulins, including HUMULIN R U-500, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
Immunogenicity As with all therapeutic proteins, insulin administration may cause anti-insulin antibodies to form. The presence of antibodies that affect clinical efficacy may necessitate dose adjustments to correct for tendencies toward hyper- or hypoglycemia. The incidence of antibody formation with HUMULIN R U-500 is unknown.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations).
Animal reproduction studies were not performed. The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7% and has been reported to be as high as 20-25% in women with a HbA1c >10%. The estimated background risk of miscarriage for the indicated population is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications.
Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity. Data Human Data While available studies cannot definitively establish the absence of risk, published data from retrospective studies, open-label, randomized, parallel studies and meta-analyses over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes.
All available studies have methodological limitations, including lack of blinding, unclear methods or randomization, and small sample size.
Mechanism of action
12.1 Mechanism of Action Regulation of glucose metabolism is the primary activity of insulins, including HUMULIN R U-500. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics In a euglycemic clamp study of 24 healthy obese subjects (BMI=30-39 kg/m 2), single doses of HUMULIN R U-500 at 50 units (0.4-0.6 unit/kg) and 100 units (0.8-1.3 unit/kg) resulted in a mean time of onset of action of less than 15 minutes at both doses and a mean duration of action of 21 hours (range 13-24 hours). The time action characteristics reflect both prandial and basal activity, consistent with clinical experience.
This effect has been attributed to the high concentration of the preparation. Figure 1 should be considered a representative example since the time course of action of insulin may vary in different individuals or within the same individual. The rate of insulin absorption and consequently the onset of activity is known to be affected by the site of injection, exercise, and other variables [see Warnings and Precautions (5.3)].
Figure 1: Mean Insulin Activity Versus Time Profiles After Subcutaneous Injection of a 100 U Dose of HUMULIN R U-500 in Healthy Obese Subjects Figure 1
Pharmacokinetics
Elimination — Mean apparent half-life after subcutaneous administration of single doses of 50 units and 100 units to healthy obese subjects (N≥21) was approximately 4.5 hours (range=1.9-10 hours) for HUMULIN R U-500.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption — In a euglycemic clamp study of 24 healthy obese subjects, the median peak insulin level occurred between 4 hours (50 unit dose) and 8 hours (100 unit dose) with a range of 0.5-8 hours.
Metabolism — The uptake and degradation of insulin occurs predominantly in liver, kidney, muscle, and adipocytes, with the liver being the major organ involved in the clearance of insulin.
Elimination — Mean apparent half-life after subcutaneous administration of single doses of 50 units and 100 units to healthy obese subjects (N≥21) was approximately 4.5 hours (range=1.9-10 hours) for HUMULIN R U-500. Figure 2: Mean Serum Insulin Concentrations Versus Time After Subcutaneous Injection of a 100 U Dose of HUMULIN R U-500 Healthy Obese Subjects Figure 2
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Regular, Insulin (recombinant DNA human) |
| PNF listing | Inj.: 100 IU/mL, 3 mL pre-filled syringe (SC, IV/IM) |
| PNF listing | Inj.: 100 IU/mL, 5 mL and 10 mL vial (SC, IV/IM) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Humulin R U-500 KwikPen · Eli Lilly and Company [US FDA-approved label, version 41, July 1, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b60e8dd0-1d48-4dc9-87fd-e14675255e8c
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .